New hope for HAE patients: phase 3 trial of C1-INH aims to stop painful swelling attacks
NCT ID NCT06361537
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times
Summary
This study tests an intravenous medicine called C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The trial includes 124 participants aged 2 and older who have frequent attacks. The goal is to see if the medicine provides quick symptom relief and can prevent attacks before medical procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HEREDITARY ANGIO EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Octapharma Research Site
RECRUITINGCentennial, Colorado, 80112, United States
-
Octapharma Research Site
RECRUITINGFarmington Hills, Michigan, 48334, United States
-
Octapharma Research Site
RECRUITINGToledo, Ohio, 43617, United States
-
Octapharma Research Site
NOT_YET_RECRUITINGTirana, Albania
-
Octapharma Research Site
NOT_YET_RECRUITINGRosario, Argentina
-
Octapharma Research Site
RECRUITINGYerevan, Armenia
-
Octapharma Research Site
RECRUITINGSofia, 1431, Bulgaria
-
Octapharma Research Site
NOT_YET_RECRUITINGLima, Mexico
-
Octapharma Research Site
NOT_YET_RECRUITINGMexico City, 06720, Mexico
-
Octapharma Research Site
NOT_YET_RECRUITINGPodgorica, Montenegro
-
Octapharma Research Site
WITHDRAWNLima, 15001, Peru
-
Octapharma Research Site
NOT_YET_RECRUITINGLima, 15076, Peru
-
Octapharma Research Site
NOT_YET_RECRUITINGLima, Peru
-
Octapharma Research Site
RECRUITINGCluj-Napoca, 400162, Romania
-
Octapharma Research Site
RECRUITINGKragujevac, 11221, Serbia
-
Octapharma Research Site
NOT_YET_RECRUITINGAnkara, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGIstanbul, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGIzmir, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGSakarya, Turkey (Türkiye)
-
Octapharma Research Site
RECRUITINGKyiv, 03057, Ukraine
-
Octapharma Research Site
RECRUITINGLviv, 79010, Ukraine
-
Octapharma Research Site
NOT_YET_RECRUITINGLviv, 79035, Ukraine
Conditions
Explore the condition pages connected to this study.